Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 239 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma August 10, 2023 Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia June 5, 2018 What to Know About Exercising During Prostate Cancer: An Expert Q&A August 8, 2023 When He Said His Mother-In-Law Was Going To Live In The... March 6, 2019 Load more HOT NEWS ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays... Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers Easy Meals at Home New on NCI’s Websites for June 2020
